The manufacturer of the antifungal medication Mycamine has settled a whistleblower lawsuit in Philadelphia for $7.3 million.
Under terms of the settlement with the U.S. Department of Justice, Astellas Pharma US Inc., agreed to pay $4.2 million to the federal government and $3.1 million to states that paid for the drug through Medicaid. More than $700,000 of the settlement amount will be paid to Frank Smith, a sales representative who blew the whistle on the company. The federal False Claims Act
- Learn more about Whistleblower Litigation